Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
1.91 USD -1.29% Intraday chart for Esperion Therapeutics, Inc. -31.54% -36.12%
Mar. 25 Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol DJ
Mar. 25 Sector Update: Health Care Stocks Steady Premarket Monday MT

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapies
100.0 %
75 100.0 % 116 100.0 % +54.14%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
75 100.0 % 116 100.0 % +54.14%

Managers

Managers TitleAgeSince
Sheldon Koenig CEO
 Chief Executive Officer 58 20-12-14
Benjamin Halladay DFI
 Director of Finance/CFO 38 19-12-31
JoAnne Foody CTO
 Chief Tech/Sci/R&D Officer 59 21-06-27
Glenn Brame CTO
 Chief Tech/Sci/R&D Officer 67 23-01-31
Alexis Callahan IRC
 Investor Relations Contact - -
Betty Jean PRN
 Corporate Officer/Principal - 21-01-31
Benjamin Looker LAW
 General Counsel 42 21-12-31
Marianne Andreach PRN
 Corporate Officer/Principal - -
Eric Warren PRN
 Corporate Officer/Principal 76 20-12-31

Members of the board

Members of the board TitleAgeSince
Stephen Rocamboli BRD
 Director/Board Member 52 22-04-27
J. Carroll CHM
 Chairman 74 22-05-31
Alan Fuhrman BRD
 Director/Board Member 67 20-03-15
Antonio M. Gotto BRD
 Director/Board Member 88 14-01-13
Nicole Vitullo BRD
 Director/Board Member 66 08-03-31
Jay Shepard BRD
 Director/Board Member 66 18-05-28
Seth Fischer BRD
 Director/Board Member 68 21-10-27
Tracy M. Woody BRD
 Director/Board Member 54 19-04-30
Sheldon Koenig CEO
 Chief Executive Officer 58 20-12-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 191,394,765 188,547,683 ( 98.51 %) 1,994,198 ( 1.042 %) 98.51 %

Shareholders

NameEquities%Valuation
Bellevue Asset Management AG
5.395 %
9,194,064 5.395 % 25 M $
Wasatch Advisors, Inc.
5.217 %
8,891,103 5.217 % 24 M $
Two Seas Capital LP
4.510 %
7,686,120 4.510 % 21 M $
Vanguard Global Advisers LLC
3.015 %
5,137,750 3.015 % 14 M $
Deerfield Management Co. LP
2.934 %
5,000,000 2.934 % 13 M $
Bellevue Asset Management AG
2.467 %
4,204,264 2.467 % 11 M $
Meditor Group Ltd.
2.225 %
3,791,300 2.225 % 10 M $
Millennium Management LLC
2.024 %
3,449,451 2.024 % 9 M $
Armistice Capital LLC
1.878 %
3,200,000 1.878 % 9 M $
Platinum Investment Management Ltd.
1.649 %
2,810,555 1.649 % 8 M $

Company contact information

Esperion Therapeutics, Inc.

3891 Ranchero Drive Suite 150

48108, Ann Arbor

+734 887 3903

http://www.esperion.com
address Esperion Therapeutics, Inc.(ESPR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for Esperion Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
1.935 USD
Average target price
7.414 USD
Spread / Average Target
+283.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ESPERION THERAPEUTICS, INC. Stock Esperion Therapeutics, Inc.
-36.45% 366M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+28.46% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.27% 559B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.60% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.03% 320B
ABBVIE INC. Stock AbbVie Inc.
+5.07% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.62% 213B
NOVARTIS AG Stock Novartis AG
+0.15% 207B
ROCHE HOLDING AG Stock Roche Holding AG
-9.41% 199B
AMGEN INC. Stock Amgen Inc.
-7.65% 142B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. Company Esperion Therapeutics, Inc.